Kyverna Therapeutics Inc.
Organization details
- Legal name
- Kyverna Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Emeryville
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KYTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001994702
- EIN
- 83-1365441
Board of directors
-
Andrew Craig Miller · DirectorSince 2026
- Since 2024
-
Brian L. Kotzin · DirectorSince 2024
-
Christi Shaw · Director · Executive ChairpersonSince 2024
- Since 2024
- Since 2024
- Since 2024
-
Mert Aktar · DirectorSince 2024
-
Peter Maag · Director · Chief Executive OfficerSince 2024
-
Sravan Kumar Emany · DirectorSince 2026
-
Stephen Constantine Liapis · DirectorSince 2024
-
Warner Weston Biddle · Director · Chief Executive OfficerSince 2024
Chief executives
Director election results
Annual meeting of May 27, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
90.6%
-
99.3%
Board connections
8 of this board's directors also sit on 23 other boards. 21 are in the same sector.
-
CareDx Inc. Same sectorvia Fred E. Cohen and Peter Maag
-
Progyny Inc. Same sectorvia Beth C. Seidenberg and Fred E. Cohen
-
Alto Neuroscience Inc. Same sectorvia Andrew Craig Miller
-
Atara Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
- via Christi Shaw
-
Beam Therapeutics Inc. Same sectorvia Christi Shaw
-
BioMarin Pharmaceutical Inc. Same sectorvia Ian T. Clark
-
Corvus Pharmaceuticals Inc. Same sectorvia Ian T. Clark
- via Ian T. Clark
-
Guardant Health Inc. Same sectorvia Ian T. Clark
-
Intellia Therapeutics Inc. Same sectorvia Fred E. Cohen
-
Latigo Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Maze Therapeutics Inc. Same sectorvia Daniel K. Spiegelman
-
Myriad Genetics Inc. Same sectorvia Daniel K. Spiegelman
-
Olema Pharmaceuticals Inc. Same sectorvia Ian T. Clark
-
Rigel Pharmaceuticals Inc. Same sectorvia Brian L. Kotzin
-
Sagimet Biosciences Inc. Same sectorvia Beth C. Seidenberg
-
Spruce Biosciences Inc. Same sectorvia Daniel K. Spiegelman
-
Takeda Pharmaceutical Company Limited Same sectorvia Ian T. Clark
-
Tectonic Therapeutic Inc. Same sectorvia Ian T. Clark
-
UroGen Pharma Ltd. Same sectorvia Fred E. Cohen
-
Vera Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
vTv Therapeutics Inc. Same sectorvia Daniel K. Spiegelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,999,995
- 2 purchases by 2 insiders
- Sold, last 12 months
- $292,776
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 27, 2026 | Ian T. Clark Director | Grant or award | +5,093 | — | — |
| May 27, 2026 | Fred E. Cohen Director | Grant or award | +5,093 | — | — |
| May 27, 2026 | Beth C. Seidenberg Director | Grant or award | +5,093 | — | — |
| May 27, 2026 | Christi Shaw Director, Officer (Executive Chairperson) | Shares withheld for tax | −4,194 | $8.59 | $36,026 |
| May 27, 2026 | Mert Aktar Director | Grant or award | +5,093 | — | — |
| Mar 13, 2026 | GEHCHAN NAJI Officer (See Remarks) | Grant or award | +18,000 | — | — |
| Mar 13, 2026 | GRASSO MARC Officer (Chief Financial Officer) | Grant or award | +10,000 | — | — |
| Mar 13, 2026 | Warner Weston Biddle Director, Officer (Chief Executive Officer) | Grant or award | +58,000 | — | — |
| Feb 24, 2026 | Andrew Craig Miller Director | Grant or award | +11,006 | — | — |
| Feb 24, 2026 | Sravan Kumar Emany Director | Grant or award | +11,006 | — | — |
| Jan 12, 2026 | Christi Shaw Director, Officer (Executive Chairperson) | Grant or award | +30,000 | — | — |
| Jan 12, 2026 | Christi Shaw Director, Officer (Executive Chairperson) | Grant or award | +24,301 | — | — |
| Dec 18, 2025 | Beth C. Seidenberg Director | Open-market purchase | +133,333 | $7.50 | $999,998 |
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. 10% owner | Open-market purchase | +133,333 | $7.50 | $999,998 |
| Dec 15, 2025 | Walker Karen Marie Officer (Chief Technology Officer) | Option exercise | +23,998 | $4.83 | $115,910 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Kyverna Therapeutics Inc.
Who is the CEO of Kyverna Therapeutics Inc.?
Warner Weston Biddle has been Kyverna Therapeutics Inc.'s Chief Executive Officer since September 2024.
How many directors are on Kyverna Therapeutics Inc.'s board?
Kyverna Therapeutics Inc.'s board has 12 directors: Andrew Craig Miller, Beth C. Seidenberg, Brian L. Kotzin, Christi Shaw, Daniel K. Spiegelman, Fred E. Cohen, Ian T. Clark, Mert Aktar, Peter Maag, Sravan Kumar Emany and 2 others.
Are Kyverna Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Kyverna Therapeutics Inc. insiders bought $2.0 million of shares in 2 purchases and sold $292,776 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="kyverna-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.